Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis
Date
2018-11-26
Authors
Abastabar, Mahdi
Haghani, Iman
Shokohi, Tahereh
Hedayati, Mohammad Taghi
Aghili, Seyed Reza
Jedi, Ali
Dadashi, Sulmaz
Shabanzadeh, Shafigheh
Hosseini, Tahereh
Aslani, Narges
Journal Title
Journal ISSN
Volume Title
Publisher
American Society for Microbiology
Abstract
The in vitro activity of tavaborole, an FDA-approved antifungal drug, was compared to that of four antifungal agents against 170 clinical fungal isolates originating from patients with onychomycosis. Tavaborole had low activity against all isolates compared to itraconazole, terbinafine, and fluconazole, the principal choices for treatment of onychomycosis. Thus, it appears that tavaborole is not a candidate for the treatment of onychomycosis due to Candida species, Aspergillus species, and dermatophytes.
Description
Keywords
tavaborole, antifungal, onychomycosis
Citation
Abastabar, M., Haghani, I., Shokohi, T., Hedayati, M. T., Aghili, S. R., Jedi, A., . . . Badali, H. (2018). Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis. Antimicrobial Agents and Chemotherapy, 62(12), 10.1128/aac.01632-01618. doi:10.1128/aac.01632-18
Department
Molecular Microbiology and Immunology